Bevacizumab every 4 weeks is as effective as every 2 weeks in combination with biweekly FOLFIRI in metastatic colorectal cancer


Yildiz R., Benekli M., ÖZKAN M. , Alkis N., Berk V., Kaplan M. A. , ...Daha Fazla

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, cilt.138, ss.1845-1852, 2012 (SCI İndekslerine Giren Dergi) identifier

  • Cilt numarası: 138 Konu: 11
  • Basım Tarihi: 2012
  • Doi Numarası: 10.1007/s00432-012-1264-5
  • Dergi Adı: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
  • Sayfa Sayıları: ss.1845-1852

Özet

The efficacy and tolerability of bevacizumab every 2 or 4 weeks using the same dosage in combination with biweekly FOLFIRI were retrospectively evaluated in metastatic colorectal cancer (mCRC) patients in the first-line and second-line therapy.